Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.43 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.42 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30821975 | 1.00 | L3MBTL1 (0.45) | L3MBTL1POLBKMT2AMEN1PDK2 | |
| SCHEMBL14891093 | 1.00 | L3MBTL1 (0.45) | L3MBTL1POLBKMT2AMEN1PDK2 | |
| SCHEMBL29402007 | 1.00 | L3MBTL1 (0.45) | L3MBTL1POLBKMT2AMEN1PDK2 | |
| SCHEMBL6955887 | 0.96 | CHRM2 (0.42) | L3MBTL1POLBKMT2AMEN1PDK2 | |
| SCHEMBL30821987 | 0.89 | KMT2A (0.41) | KMT2AFABP7FABP5CHRM3EPHX2 | |
| SCHEMBL18148919 | 0.89 | KMT2A (0.47) | KMT2AFABP7FABP5CHRM3EPHX2 | |
| SCHEMBL10118378 | 0.89 | NPC1 (0.45) | L3MBTL1KMT2AMEN1FABP7FABP5 | |
| SCHEMBL29600664 | 0.89 | KMT2A (0.41) | KMT2AFABP7FABP5CHRM3EPHX2 | |
| SCHEMBL7096605 | 0.89 | KMT2A (0.41) | KMT2AFABP7FABP5CHRM3EPHX2 | |
| SCHEMBL6309080 | 0.89 | KMT2A (0.41) | KMT2AFABP7FABP5CHRM3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034093-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20240358675-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| EP-3252057-B1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-20200323819-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-10-15 | — | — | US | disclosed |
| US-20190125722-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-10085968-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2018-10-02 | — | — | US | disclosed |
| EP-2933333-B1 | SINGLE-STRAND NUCLEIC ACID MOLECULE FOR CONTROLLING GENE EXPRESSION | BONAC CORP (JP) | 2018-02-21 | — | — | EP | disclosed |
| EP-3252057-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2431466-A1 | SINGLE-STRAND NUCLEIC ACID MOLECULE FOR CONTROLLING GENE EXPRESSION | Bonac Corporation (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20120035246-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING NITROGEN-CONTAINING ALICYCLIC SKELETON | BONAC CORPORATION (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120035246-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING NITROGEN-CONTAINING ALICYCLIC SKELETON | BONAC CORPORATION (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120010271-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE FOR CONTROLLING GENE EXPRESSION | BONAC CORPORATION (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20120010271-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE FOR CONTROLLING GENE EXPRESSION | BONAC CORPORATION (JP) | 2012-01-12 | — | — | US | disclosed |
| WO-2011069063-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011069063-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
| EP-1140952-B1 | ORGANO-PHOSPHORUS COMPOUNDS AND THEIR UTILIZATION | BIOAGENCY AG (DE) | 2003-09-03 | — | — | EP | disclosed |
| EP-1140952-A1 | ORGANO-PHOSPHORUS COMPOUNDS AND THEIR UTILIZATION | Jomaa Pharmaka GmbH (DE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037477-A1 | ORGANO-PHOSPHORUS COMPOUNDS AND THEIR UTILIZATION | JOMAA PHARMAKA GMBH (DE) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010271-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE FOR CONTROLLING GENE EXPRESSION | SRRT, SSU72, RPRD2 | L3MBTL1 118/4885POLB 505/4885KMT2A 1767/4885 |
| US-20190125722-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | L3MBTL1 3735/4885POLB 2699/4885KMT2A 2379/4885 |
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | L3MBTL1 3735/4885POLB 2699/4885KMT2A 2379/4885 |
| US-20200323819-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | L3MBTL1 3735/4885POLB 2699/4885KMT2A 2379/4885 |
| US-20240358675-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | L3MBTL1 3735/4885POLB 2699/4885KMT2A 2379/4885 |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | GRIN2C, NLN, COMT | L3MBTL1 3735/4885POLB 2699/4885KMT2A 2379/4885 |
| US-10085968-B2 | Multicyclic compounds and methods of use thereof | GRIN2A, AVPR1A, GRIN2C | L3MBTL1 1937/4885POLB 2156/4885KMT2A 859/4885 |
| US-20260034093-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SLC6A3, SLC6A11, SLC6A13 | L3MBTL1 4557/4885POLB 4657/4885KMT2A 2581/4885 |
| US-20120035246-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING NITROGEN-CONTAINING ALICYCLIC SKELETON | NSUN2, CTDSP1, RNGTT | L3MBTL1 188/4885POLB 112/4885KMT2A 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.